<table id="_Ref381622093" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3:     Established and Other Potentially Significant Drug Interactions</caption>
<col width="33%"></col>
<col width="17%"></col>
<col width="50%"></col>
<thead>
<tr>
<th align="left" stylecode="Rrule Botrule Toprule " valign="top">
<content stylecode="bold">Concomitant Drug Class:<br/>Drug Name</content>
</th>
<th align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<content stylecode="bold">Effect on Concentration<sup>a</sup>
</content>
</th>
<th align="center" stylecode="Botrule Lrule Toprule " valign="top">
<content stylecode="bold">Clinical Comment</content>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3" stylecode="Botrule" valign="top">
<sup>a</sup>   The direction of the arrow (↑ = increase, ↓ = decrease) indicates the direction of the change in pharmacokinetic parameters.<br/>
<sup>b</sup>   These interactions have been studied [<content stylecode="emphasis">
<content stylecode="italics">see <linkhtml href="#ID_fd973a06-63f8-4471-a2de-584c0a88e03d">Clinical Pharmacology (12.3</linkhtml>, Tables 5 and 6)</content>
</content>].</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Strong CYP3A inhibitors</content>
</paragraph>
</td>
<td stylecode="Toprule Botrule "></td>
<td stylecode="Toprule Botrule "></td>
</tr>
<tr>
<td stylecode="Rrule Toprule Botrule ">
<paragraph>Examples: atazanavir/ritonavir,<sup>b</sup> clarithromycin, indinavir, itraconazole, ketoconazole,<sup>b</sup> nefazodone, nelfinavir, posaconazole, saquinavir, telithromycin, voriconazole</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>↑ Daclatasvir</paragraph>
</td>
<td stylecode="Lrule Toprule Botrule ">
<paragraph>Decrease DAKLINZA dose to 30 mg once daily when coadministered with strong inhibitors of CYP3A.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Moderate CYP3A inhibitors</content>
</paragraph>
</td>
<td stylecode="Toprule Botrule "></td>
<td stylecode="Toprule Botrule "></td>
</tr>
<tr>
<td stylecode="Rrule Toprule Botrule ">
<paragraph>Examples: atazanavir, ciprofloxacin, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>↑ Daclatasvir</paragraph>
</td>
<td stylecode="Lrule Toprule Botrule ">
<paragraph>Monitor for daclatasvir adverse events.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Moderate CYP3A inducers</content>
</paragraph>
</td>
<td stylecode="Toprule Botrule "></td>
<td stylecode="Toprule Botrule "></td>
</tr>
<tr>
<td stylecode="Rrule Toprule Botrule ">
<paragraph>Examples:  bosentan, dexamethasone, efavirenz,<sup>b</sup> etravirine, modafinil, nafcillin, rifapentine</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>↓ Daclatasvir</paragraph>
</td>
<td stylecode="Lrule Toprule Botrule ">
<paragraph>Increase DAKLINZA dose to 90 mg once daily when coadministered with moderate inducers of CYP3A.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Anticoagulants</content>
</paragraph>
</td>
<td stylecode="Toprule Botrule "></td>
<td stylecode="Toprule Botrule "></td>
</tr>
<tr>
<td stylecode="Rrule Toprule Botrule ">
<paragraph>Dabigatran etexilate mesylate</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>↑ Dabigatran</paragraph>
</td>
<td stylecode="Lrule Toprule Botrule ">
<paragraph>Use of DAKLINZA with dabigatran etexilate is not recommended in specific renal impairment groups, depending on the indication. Please see the dabigatran prescribing information for specific recommendations.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Cardiovascular agents</content>
</paragraph>
</td>
<td stylecode="Toprule Botrule "></td>
<td stylecode="Toprule Botrule "></td>
</tr>
<tr>
<td stylecode="Rrule Toprule Botrule ">
<paragraph>Antiarrhythmic:<br/>   Amiodarone</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>
<br/>Amiodarone: effects unknown</paragraph>
</td>
<td stylecode="Lrule Toprule Botrule ">
<paragraph>
<br/>Coadministration of amiodarone with DAKLINZA in combination with sofosbuvir is not recommended because it may result in serious symptomatic bradycardia. The mechanism of this effect is unknown. If coadministration is required, cardiac monitoring is recommended. [<content stylecode="italics">See <linkhtml href="#ID_373737c1-1c3d-432d-8bc5-64cbc8867b32">Warnings and Precautions (5.2)</linkhtml> and <linkhtml href="#ID_4225c82a-ae5b-4b78-82ce-dcbff5089df5">Adverse Reactions (6.2)</linkhtml>.</content>]</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Toprule Botrule ">
<paragraph>Antiarrhythmic:<br/>   Digoxin<sup>b</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>
<br/>↑ Digoxin</paragraph>
</td>
<td stylecode="Lrule Toprule Botrule ">
<paragraph>
<br/>
<content stylecode="underline">Patients already receiving daclatasvir initiating digoxin</content>: Initiate treatment using the lowest appropriate digoxin dosage. Monitor digoxin concentrations; adjust digoxin doses if necessary and continue monitoring.</paragraph>
<paragraph> </paragraph>
<paragraph>
<content stylecode="underline">Patients already receiving digoxin prior to initiating daclatasvir</content>: Measure serum digoxin concentrations before initiating daclatasvir. Reduce digoxin concentrations by decreasing digoxin dosage by approximately 30% to 50% or by modifying the dosing frequency and continue monitoring.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule ">
<paragraph>
<content stylecode="italics">Lipid-lowering agents</content>
</paragraph>
</td>
<td stylecode="Toprule Botrule "></td>
<td stylecode="Toprule Botrule "></td>
</tr>
<tr>
<td stylecode="Rrule Botrule Toprule ">
<paragraph>HMG-CoA reductase inhibitors:<br/>   Atorvastatin<br/>   Fluvastatin<br/>   Pitavastatin<br/>   Pravastatin</paragraph>
<paragraph>   Rosuvastatin<sup>b</sup>
<br/>   Simvastatin</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule Toprule ">
<paragraph>
<br/>↑ Atorvastatin<br/>↑ Fluvastatin<br/>↑ Pitavastatin<br/>↑ Pravastatin<br/>↑ Rosuvastatin<br/>↑ Simvastatin</paragraph>
</td>
<td stylecode="Botrule Lrule Toprule ">
<paragraph>
<br/>Monitor for HMG-CoA reductase inhibitor associated adverse events such as myopathy.</paragraph>
</td>
</tr>
</tbody>
</table>